Epidemiology and Genomics Research Funding Opportunities

The Epidemiology and Genomics Research Program (EGRP) provides funding support for research in human populations to understand the causes of cancer and related outcomes. EGRP is the largest funder of cancer epidemiology grants nationally and worldwide. In addition to supporting investigator-initiated research grants, EGRP sponsors or co-sponsors a variety of targeted funding opportunity announcements (FOAs), and also is inviting participation in a prize competition. Here we provide a listing of funding opportunities that are currently accepting applications. Please visit this page regularly as new funding opportunities are added upon approval by NCI.


FOAs Sponsored/Co-Sponsored by EGRP

NOTE: The following table lists the newest FOAs at the top of the table.

FOAs Sponsored/Co-Sponsored
by EGRP
Announcement Number
(Grant Mechanism)
Submission Dates Expiration Date
"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers
Summary Details
PA-16-426External Web Site Policy (R01)
PA-16-425External Web Site Policy (R21)
Standard AIDS dates applyExternal Web Site Policy Sept. 8, 2019

Summary:
The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. This FOA encourages research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection. For more information: PA-16-426External Web Site Policy (R01) and PA-16-425External Web Site Policy (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov; and Vaurice Starks, Program Director, Environmental Epidemiology Branch, e-mail: starksv@mail.nih.gov

Secondary Analyses of Alcohol and Chronic Disease
Summary Details
PA-16-395External Web Site Policy (R01)
PA-16-394External Web Site Policy (R03)
Standard dates applyExternal Web Site Policy Sept. 8, 2019

Summary:
This FOA encourages use of existing datasets to examine associations between alcohol and non-communicable chronic diseases. A population of particular interest is older adults, however, other populations that are understudied may be considered, including but not limited to pregnant women, pre-and post-menopausal women, cancer survivors, and other populations defined by stage-of-life and race/ethnicity. Factors of interest that may interact with alcohol include, but are not limited to, concurrent use of prescription or illicit drugs, lifestyle factors such as smoking, diet, and physical activity, and genetics including gene-environment interactions. Alcohol may be considered in numerous ways, including, but not limited to, average volume, quantity/frequency, binge, drinking with meals, lifetime drinking, and presence of alcohol use disorders. Studies examining both the benefits and harms of drinking are of interest as well as studies of moderate and heavy drinking. Sources of data may include, but are not limited to previously conducted epidemiologic studies (cross-sectional or cohort) and clinical trials. For more information: PA-16-395External Web Site Policy (R01) and PA-16-394External Web Site Policy (R03).

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: mahabir@mail.nih.gov

Exploratory Grants in Cancer Epidemiology and Genomics Research
Summary Details
PA-16-175External Web Site Policy (R21) Standard dates applyExternal Web Site Policy May 8, 2019

Summary:
This FOA invites applications for research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research, such as improving epidemiologic study data collection; validating measurement of exposures in body fluids and tissues; applying epigenetic or metabolomic approaches to cancer epidemiology research; developing and applying novel strategies for discovery of risk variants for rare cancers; understanding the population genetic architecture of cancer in understudied populations; or validating methods to extract, collect, and synthesize clinical data via electronic medical records for use in observational studies of cancer patients and survivors. For more information: PA-16-175External Web Site Policy (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Obesity Policy Evaluation Research
Summary Details
PA-16-165External Web Site Policy (R01) Standard dates applyExternal Web Site Policy May 8, 2019

Summary:
This FOA encourages applications that propose to evaluate large scale policy or programs that are expected to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. For more information: PA-16-165External Web Site Policy (R01).

Contact: Jill Reedy, Ph.D., M.P.H., R.D., Program Director, Risk Factor Assessment Branch, e-mail: reedyj@mail.nih.gov

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity
Summary Details
PA-16-035External Web Site Policy (R01)
PA-16-036External Web Site Policy (R21)
Standard dates applyExternal Web Site Policy Jan. 8, 2019

Summary:
This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE). For more information: PA-16-035External Web Site Policy (R01) and PA-16-036External Web Site Policy (R21).

Contact: Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N., Program Director, Clinical and Translational Epidemiology Branch; e-mail: nonniekaye.shelburne@nih.gov

Social Epigenomics Research Focused on Minority Health and Health Disparities
Summary Details
PAR-16-355External Web Site Policy (R01) Nov. 15, 2016
Nov. 15, 2017
Nov. 15, 2018
Nov. 16, 2018

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and health disparity populations. For more information: PAR-16-355External Web Site Policy (R01).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Diet and Physical Activity Assessment Methodology
Summary Details
PA-16-167External Web Site Policy (R01)
PAR-15-171External Web Site Policy (R21)

R01: Standard dates applyExternal Web Site Policy.

New R21 applications: Oct. 16, 2015; June 16, 2016; Feb. 16, 2017; Oct. 16, 2017; and June 16, 2018 (alternating standard due dates)

R21 resubmission applications: Nov. 16, 2015; July 16, 2016; Mar. 16, 2017; Nov. 16, 2017; and July 16, 2018 (alternating standard due dates)

May 8, 2019 (R01)
Sept. 8, 2018 (R21)

Summary:
These FOAs encourage innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under these FOAs are encouraged to include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. Several other NIH Institutes are also cosponsors of these FOAs. For more information: PA-16-167External Web Site Policy (R01) and PAR-15-171External Web Site Policy (R21).

For diet assessment questions: Amy Subar, Ph.D., Program Director, Risk Factor Assessment Branch, e-mail: subara@mail.nih.gov

For physical activity assessment questions: Richard Troiano, Ph.D., Program Director, Risk Factor Assessment Branch, e-mail: troianor@mail.nih.gov

Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention
Summary Details
PAR-15-308External Web Site Policy (R01)
PAR-15-309External Web Site Policy (R21)
Nov. 23, 2015
July 11 and Nov. 22, 2016
July 11 and Nov. 21, 2017
July 11, 2018
July 12, 2018

Summary:
These FOAs, co-sponsored by NCI and the National Institute of Environmental Health Sciences (NIEHS) encourage research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. For more information: PAR-15-308External Web Site Policy (R01) and PAR-15-309External Web Site Policy (R21).

Contact: Gabriel Lai, Ph.D., Program Director, Environmental Epidemiology Branch; e-mail: laigy@mail.nih.gov

Translational Research on Adducts in Cancer Risk Identification and Prevention
Summary Details
PAR-15-307External Web Site Policy (U01) Nov. 23, 2015
July 11 and Nov. 22, 2016
July 11 and Nov. 21, 2017
July 11, 2018
July 12, 2018

Summary:
This FOA, co-sponsored by NCI and the National Institute of Environmental Health Sciences (NIEHS), encourages clinically-relevant translational/epidemiological research projects focused on the use of adducts to cellular macromolecules, as indicators of exposures to cancer risk factors in human populations and subgroups. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The projects are expected to be based on comprehensive use of human biospecimens for which detailed medical data are available (e.g., biospecimens from the NCI-supported cohort studies). The main emphasis of this FOA is on advancing the area of cancer detection, cancer prevention, and assessing cancer risks in human populations and subgroups. For more information: PAR-15-307External Web Site Policy (U01).

Contact: Gabriel Lai, Ph.D., Program Director, Environmental Epidemiology Branch; e-mail: laigy@mail.nih.gov

Early-life Factors and Cancer Development Later in Life
Summary Details
PA-15-124External Web Site Policy (R03)
PA-15-125External Web Site Policy (R21)
PA-15-126External Web Site Policy (R01)
Standard dates applyExternal Web Site Policy Jan. 8, 2018

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. In particular, this FOA supports research efforts that will help illuminate 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies. For more information: PA-15-124External Web Site Policy (R03), PA-15-125External Web Site Policy (R21), and PA-15-126External Web Site Policy (R01).

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: mahabir@mail.nih.gov

Turkey-US Collaborative Program for Affordable Medical Technologies
Summary Details
PAR-15-276External Web Site Policy (R01) Standard dates applyExternal Web Site Policy Jan. 8, 2018

Summary:
This FOA invites applications from research partnerships formed between U.S. and Turkish scientists to aid the development of appropriate affordable diagnostic and therapeutic technologies to address medical needs in low-middle resource settings. Appropriate medical technologies are those that are useable, cost effective, sustainable, and effective in meeting a significant clinical need in a lower-middle resource setting in different world regions. The FOA encourages efforts towards developing or reengineering existing medical technologies to make them affordable and efficient so that they will have a significant impact on cancer. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is a cosponsor of this FOA. For more information: PA-14-276External Web Site Policy (R01).

Contact: Rao L. Divi, Ph.D., Program Director, Methods and Technologies Branch, e-mail: divir@mail.nih.gov

Ethical, Legal, Social Implications of Human Genome Research
Summary Details
PA-14-276External Web Site Policy (R01) R01: Feb. 5, June 5, and Oct. 5 Sept. 8, 2017

Summary:
This PA invites multidisciplinary research applications that identify, examine, and address the ethical, legal, and social implications (ELSI) of advances in genomic research and technology for individuals, families, communities, and society more broadly. NCI is interested in empirical research that focuses on the ethical, legal, and social issues related to heritable cancer syndromes. Study of the psychosocial and behavioral impact on affected individuals, their families, and populations and research that takes into consideration the perpsectives of diverse racial, ethnic, and socioeconomic backgrounds, as well as children, older adults, and people with disabilities, is highly desirable. The ultimate goal of this research will be to improve outcomes related to the diagnosis of heritable cancer syndromes. The National Human Genome Research Institute (NHGRI) is the lead sponsor of the PA; several other NIH Institutes also are cosponsors. For more information: PA-14-276External Web Site Policy (R01).

Contact: Charlisse Caga-anan, J.D., Program Director, Genomic Epidemiology Branch, e-mail: cagaananef@mail.nih.gov

Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection
Summary Details
PAR-14-254External Web Site Policy (R21)
PAR-14-255External Web Site Policy (R01)
Standard AIDS dates applyExternal Web Site Policy May 8, 2017

Summary:
The purpose of these FOAs is to fill gaps in the understanding of the pathogenic interactions between HIV and hepatitis viruses, co-morbidities associated with HIV/hepatitis virus co-infection, and the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV/HCV co-infection. For more information: PAR-14-254External Web Site Policy (R21) and PAR-14-255External Web Site Policy (R01).

Contact: Vaurice Starks, Program Director, Environmental Epidemiology Branch, e-mail: starksv@mail.nih.gov

Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts
Summary Details
PAR-15-104External Web Site Policy (U01) Apr. 1, July 8, and Nov. 10, 2015
Mar. 11, July 8, and Nov. 10, 2016
Mar. 10, 2017
Mar. 11, 2017

Summary:
This PAR invites grant applications to provide targeted infrastructure support for the core functions of cancer epidemiology cohorts (CECs) and methodological research. This infrastructure can support existing or new CECs. This PAR will support core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genomics Research Program (EGRP) and other components of NCI’s Division of Cancer Control and Population Sciences (DCCPS). For more information: PAR-15-104External Web Site Policy (U01) and FAQs

Contact: Joanne Elena, Ph.D., M.P.H., Program Director, Clinical and Translational Epidemiology Branch, e-mail: elenajw@mail.nih.gov

Genomic Resource Grants for Community Resource Projects
Summary Details
PAR-14-191External Web Site Policy (U41) Jan. 25, May 25, and Sept. 25, 2015
Jan. 25, May 25, and Sept. 25, 2016
Jan. 25, 2017
Jan. 26, 2017

Summary:
Awards under this FOA will support the development and distribution of genomic resources that will be available to and valuable for the broad research community, using cost-effective approaches. Such resources include (but are not limited to) informatics resources (such as human and model organism databases, ontologies, and coordinated sets of analysis tools), comprehensive identification and collections of genomic features (such as structural variants or functional genomic elements), and standard data types produced for central sets of samples (such as 1000 Genomes or GTEx samples). The National Human Genome Research Institute (NHGRI) is the lead sponsor of the FOA and NCI is a co-sponsor. For more information: PAR-14-191External Web Site Policy (U41).

Contact:: Leah Mechanic, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, e-mail: mechanil@mail.nih.gov

Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment
Summary Details
PAR-15-075External Web Site Policy (R01) Mar. 6, 2015
Thereafter, standard dates apply.
Jan. 8, 2017

Summary:
This FOA encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of technologies, methods, assays, devices, and/or systems that are designed to solve a targeted cancer problem. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following: current commercially supported systems, next-generation systems, quality assurance and quality control, validation and correlation studies, quantitative imaging, and related research resources. Applications should be translational in scope; therefore, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. Innovation may be considered as delivery of a new capability to end users. Applications should establish the academic-industrial partnership as an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their system to solve their chosen cancer problem. For more information: PAR-15-075External Web Site Policy (R01).

Contact:: Rao L. Divi, Ph.D., Program Director, Methods and Technologies Branch, e-mail: divir@mail.nih.gov


Other funding opportunities of interest not sponsored by EGRP



Stay Up to Date

Subscribe to EGRP's monthly Cancer Epidemiology E-News to receive details about recent NIH FOAs and Notices of Intent to publish an FOA, as well as relevant funding opportunities from other organizations.

Return to Top